


Materials Horizons

Volume 9
Number 3
March 2022
Pages 845–1100

rsc.li/materials-horizons



ISSN 2051-6347

COMMUNICATION

Ruibing Wang *et al.*
Enhanced antibacterial function of a supramolecular artificial
receptor-modified macrophage (SAR-Macrophage)



Cite this: *Mater. Horiz.*, 2022,
9, 934

Received 10th November 2021,
Accepted 22nd December 2021

DOI: 10.1039/d1mh01813b

rsc.li/materials-horizons

Enhanced antibacterial function of a supramolecular artificial receptor-modified macrophage (SAR-Macrophage)[†]

Qian Cheng,^a Meng Xu,^a Chen Sun,^a Kuikun Yang,^a Zhiqing Yang,^a Junyan Li,^a
Jun Zheng,^b Ying Zheng^{ab} and Ruibing Wang^{id}*^{ab}

Bacterial infection has become a global concern owing to the significant morbidity and mortality. Although the phagocytosis of bacteria by immune cells acts as the front line to protect human body from invading pathogens, the relatively slow encounter and insufficient capture of bacteria by immune cells often lead to an inefficient clearance of pathogens. Herein, a supramolecular artificial receptor-modified macrophage (SAR-Macrophage) was developed to enhance the recognition and latch of bacteria in the systemic circulation, mediated *via* strong and multipoint host-guest interactions between the artificial receptors (cucurbit[7]uril) on the macrophage and the guest ligands (adamantane) selectively anchored on *Escherichia coli* (*E. coli*). As a result, the SAR-Macrophage could significantly accelerate the recognition of *E. coli*, catch and internalize more pathogens, which subsequently induced the M1 polarization of macrophages to generate ROS and effectively kill the intracellular bacteria. Therefore, the SAR-Macrophage represents a simple, yet powerful anti-bacterial approach.

Bacterial infection has attracted increasing attention due to the acquired resistance of bacteria to various antibiotics, which poses a serious threat to public health.^{1,2} To avoid antibiotic resistance, increasing studies are turning to the natural immune system to combat bacterial infection.³ Macrophages play a key role in immune protection from bacterial pathogens by recognizing, engulfing and digesting bacteria through a phagocytosis process.^{4,5} Although the macrophage endocytic process is a natural response to pathogenic bacterial infection, it is often difficult for a macrophage to efficiently encounter, latch and catch pathogens, resulting in low sensitivity and

New concepts

Reminiscent of CAR-T and CAR-Macrophage, a supramolecular artificial receptor-modified macrophage (namely, SAR-Macrophage) was developed and applied for the first time to enhance the recognition and latch of bacteria, mediated *via* strong, multipoint host-guest interactions between the artificial receptors (cucurbit[7]uril) on the macrophage, and the guest ligands (adamantane) remotely labeled on *Escherichia coli* (*E. coli*). As a result, the SAR-Macrophage could significantly accelerate the recognition of *E. coli*, catch and internalize more pathogens, which subsequently induced the M1 polarization of macrophages to generate ROS and effectively killed the intracellular bacteria. However, most of the previous works relied on the upregulation of natural surface receptors of macrophages, which may imbalance their innate immunity and inevitably lead to undesirable side effects. Herein, the bioorthogonal recognition of bacteria *via* artificial receptors may mitigate such risks. Therefore, the SAR-Macrophage not only represents a simple cell-engineering approach for antibacterial applications, but also provides important new insights to design and develop cell-based biomaterial therapeutics for diverse biomedical applications *via* an enhanced, bioorthogonal, host-guest chemistry-mediated recognition.

elimination efficiency of macrophages towards bacteria, thus inevitably leading to a high infection rate.⁶ Various strategies and mechanisms have been explored to improve the antibacterial activity of macrophages. For instance, Casanova *et al.* reported that the overexpression of BAI1 (brain angiogenesis inhibitor 1) enhanced the macrophage's encounter, engulfment and clearance of Gram-negative bacteria through the recognition of their surface lipopolysaccharides.⁷ Similarly, Chinetti-Gbaguidi *et al.* found that the pretreatment of macrophages with Liver X Receptor agonists resulted in an enhanced recognition of lipopolysaccharides and an increased reactive oxygen species (ROS) generation to exert antibacterial activities.⁸ In another study, Biswal *et al.* discovered that the activation of Nrf2 (nuclear erythroid-related factor 2) upregulated its downstream MARCO (the scavenger receptor) of defective macrophage, which was suppressed in chronic obstructive

^a State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China.

E-mail: rwang@um.edu.mo

^b Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China


[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/d1mh01813b

pulmonary disease, leading to restored bacterial recognition and phagocytosis in alveolar macrophages.⁹ In spite of these successes, all of these approaches relied on the upregulation of natural surface receptors of macrophages, which may imbalance their innate immunity and inevitably lead to undesirable side effects.^{10,11} On the other hand, numerous nanomaterials have been extensively studied as antibiotic carriers or to generate ROS to directly combat with bacteria.^{12–16} In spite of the promising antibacterial activity, these nanomaterials still face a series of obstacles, including nonspecific toxicity and increased risk of drug resistance. Herein, through simply engineering the natural macrophage with artificial receptors that have specific, bioorthogonal recognition of bacteria may mitigate various risks, such as drug-resistance and undesirable side effects.

Indeed, artificial host–guest interactions offer a new paradigm for biomedical applications, displaying advantages in enabling bio-orthogonal, specific recognition, targeting and latching *in vitro* and *in vivo*.^{17–21} For instance, Kim *et al.* leveraged an ultrastable synthetic host–guest pair between cucurbit[7]uril (CB[7]) and adamantyl-(ADA) guests for the specific and bio-orthogonal protein imaging and bioimaging *in vivo*.²² Wang *et al.* demonstrated that CB[7]-grafted hyaluronic acid could recognize, latch and aggregate ADA-modified mitochondria to further induce mitochondrial aggregation and fusion intracellularly.²³ On the basis of such a bio-orthogonal, high specificity and binding affinity between CB[7] and ADA in the complex biological environment,²⁴ and inspired by the clinical success of CAR-T (Chimeric Antigen Receptor T-cell)

and CAR-Macrophage,^{25,26} here, we designed a facile, yet powerful SAR-Macrophage (supramolecular artificial receptor macrophage), reminiscent of CAR-T and CAR-Macrophage, by anchoring CB[7] as an artificial receptor on the surface of macrophage, thus enhancing the recognition, latching and internalization of *E. coli*, which was specifically decorated with ADA as an artificial ligand, mediated *via* strong and multipoint host–guest interactions for significantly improving the antibacterial activity of the macrophage against *E. coli* (Scheme 1).

First, as D-mannose can be recognized and adsorbed onto *E. coli* owing to its strong and specific interactions with FimH (Type 1 fimbriae D-mannose specific adhesion protein) on the pathogens,¹⁹ a mannose-ADA conjugate was designed and synthesized *via* a thiol–ene click reaction between allyl- α -D-mannopyranoside and 1-adamantanethiol to decorate the surface of *E. coli* with ADA *via* mannose-FimH interactions. The synthetic route of mannose-ADA is illustrated in Fig. S1 (ESI[†]). The successful synthesis was confirmed by ¹H and ¹³C NMR spectroscopy (Fig. S2–S4, ESI[†]). As shown in Fig. S5 (ESI[†]), mannose-ADA (up to 500 $\mu\text{g mL}^{-1}$) exhibited negligible cytotoxicity against *E. coli* after incubation for 24 h *via* MTT assays. Cy5-conjugated CB[7] (CB[7]–Cy5) was subsequently applied to investigate the successful decoration of *E. coli* with ADA. As shown in Fig. S6 (ESI[†]), after incubation with CB[7]–Cy5 for 10 min, *E. coli* pre-incubated with mannose-ADA (100 $\mu\text{g mL}^{-1}$, 20 min) exhibited strong red fluorescence of Cy5 on the surface, attributed to the strong host–guest interactions between CB[7] of CB[7]–Cy5 and ADA from the *E. coli* surface. In contrast, no



Scheme 1 Supramolecular artificial receptor (SAR)-Macrophages rapidly and highly specifically recognize *E. coli* through strong and multipoint host–guest interactions, thus improving the latching and internalization of *E. coli*, and inducing M1 polarization of macrophages to generate ROS, and effectively kill the intracellular bacteria.

fluorescence was observed on the *E. coli* without pre-incubation with mannose-ADA, indicating that the successful recognition of CB[7]-Cy5 by *E. coli* was achieved via the CB[7]-ADA host-guest interaction.

SAR-Macrophage was constructed by decorating macrophage (Raw 264.7 cells) with CB[7] on the surface via simply inserting DSPE-PEG-CB[7] (1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-poly(ethylene glycol)-CB[7]) into the surface membrane of the cells.^{27,28} The amount of CB[7] on the cell surface was quantitatively determined to be approximately 0.43×10^{-12} mol per cell, by incubation of the SAR-Macrophage with ferrocene (as a strong guest molecule of CB[7]) that was quantified via ICP-MS analysis. In addition, DSPE-PEG-CB[7] exhibited negligible cytotoxicity on RAW 264.7 cells after incubation for 24 h at a concentration up to 50 μ M (Fig. S7, ESI[†]). Fluorescein isothiocyanate (FITC)-modified ADA (ADA-FITC) was utilized to evaluate the availability and stability of the surface CB[7] decorated on the macrophage. As shown in Fig. S8 (ESI[†]), RAW 264.7 cells incubated with DSPE-PEG-CB[7] for 1, 2, 4, 12 and 24 h, respectively, were subsequently treated with ADA-FITC for 5 min, and the green fluorescence of FITC maintained on the cell membrane for up to 12 h, indicating the

good stability of DSPE-PEG-CB[7] in the cell membrane. The rapid recognition and stable host-guest interactions between CB[7] and ADA may ensure efficient recognition and latch of ADA-decorated *E. coli* by the SAR-Macrophage.

We subsequently investigated the recognition and internalization of ADA-modified *E. coli* by the SAR-Macrophage. In this study, the following treatment groups were prepared: macrophages were incubated with *E. coli* (CB[7](−), ADA(−)); SAR-Macrophages were incubated with *E. coli* (CB[7](+), ADA(−)); macrophages were incubated with ADA-decorated *E. coli* (CB[7](−), ADA(+)) and SAR-Macrophages were incubated with ADA-decorated *E. coli* (CB[7](+), ADA(+)) at different multiplicity of infection (MOI) ratios ranging from 1:1 to 10:1. When the macrophages were incubated with *E. coli* at MOI = 1, strong green fluorescence from GFP-expressing *E. coli* was observed in the cytoplasm of RAW 264.7 cells in the (CB[7](+), ADA(+)) group, in contrast to the rather weak green fluorescence observed in the other three groups (Fig. 1A and Fig. S9A, ESI[†]), suggesting that the efficient recognition and internalization of ADA-decorated *E. coli* was realized by the SAR-Macrophage via strong host-guest interactions between CB[7] from the surface of the macrophage and ADA of *E. coli*. As shown in Fig. 1B, the




Fig. 1 (A) CLSM images of the macrophage infected with *E. coli* (MOI = 1) in the (CB[7] (−), ADA (+)) and (CB [7] (+), ADA (+)) groups for 1, 2 and 4 h, respectively. (B) Quantitative GFP (*E. coli*) fluorescence from A. (C) CLSM images of macrophage infected with *E. coli* (MOI = 10) in the (CB[7] (−), ADA (+)) and (CB[7] (+), ADA (+)) group for 20, 40 and 100 min, respectively. (D) Quantitative GFP (*E. coli*) fluorescence from C.

SAR-Macrophages exhibited a significantly improved recognition of *E. coli*, ca. 14-fold of that recognized by regular macrophages (quantified according to the fluorescence intensity).

When the infected *E. coli* was increased to MOI = 10, the recognition of *E. coli* by the macrophages was significantly accelerated. As shown in Fig. 1C and Fig. S9B (ESI[†]), after incubation with various formulations for 20, 40 and 100 min, the GFP fluorescence (of *E. coli*) increased more rapidly in the (CB[7](+), ADA(+)) group of macrophages, resulting in a 32-fold increase when compared with regular macrophages in 100 min, indicating that host-guest interactions indeed promoted the recognition and uptake of *E. coli* by the SAR-Macrophages (Fig. 1D). In both MOI = 1 and MOI = 10 CLSM (confocal laser scanning microscopy) images, the SAR-Macrophages were found to be morphologically deformed along with the formation of pseudopodia, indicating the polarization of macrophages to M1 would be beneficial to elimination of the intracellular bacteria. In contrast, the macrophages of other groups maintained the regular spherical morphology. The bacterial recognition and morphology of macrophages incubated with different formulations under MOI = 10 were further examined under scanning electron microscopy (SEM). As shown in Fig. 2A, abundant ADA-decorated *E. coli* were observed on the surface of the SAR-Macrophage, accompanied by the appearance of pseudopodia. In comparison, the rest three groups of macrophages showed relatively low efficiency in catching *E. coli* and exhibited a smooth cell membrane surface and a spherical shape, consistent with the observations under CLSM.

The M1 polarization of macrophages was evaluated *via* flow cytometry assays after the internalization of *E. coli* (MOI = 10). As shown in Fig. S10 (ESI[†]), in the (CB[7](+), ADA(+)) group, the M1 polarization ratio (CD11c⁺ cells) increased to 40.88% in comparison with 1.71%, 4.07%, 8.43% and 10.27% observed in

free macrophage, (CB[7](−), ADA(−)) group, (CB[7](+), ADA(−)) group and (CB[7](−), ADA(+)) group, respectively, indicating that the M1 polarization of the SAR-Macrophages was induced by the promoted recognition and arrest of *E. coli*. In addition, no M2 polarization (CD206⁺) was observed in all of these groups.

To further confirm the antibacterial efficacy of the M1-polarized macrophages, we infected different formulations of macrophages with *E. coli* at MOI = 10, followed by the evaluation of the intracellular ROS by staining with 2',7-dichlorofluorescein diacetate (DCFHDA).²⁹ According to the CLSM results (Fig. 2B), the (CB[7](+), ADA(+)) group of macrophages showed obvious intracellular green fluorescence due to the host-guest mediated recognition and arrest of *E. coli*, which promoted the intracellular ROS production. Conversely, the macrophages of other groups showed rather weak intracellular fluorescence, indicating the insufficient internalization of *E. coli* into the macrophages. The intracellular ROS generation was further quantitatively analyzed *via* flow cytometry upon DCFHDA staining. As shown in Fig. S11 (ESI[†]), the fluorescence intensity of (CB[7](+), ADA(+)) was 2.1-fold higher than that of the control group, while the (CB[7](−), ADA(−)) group, the (CB[7](+), ADA(−)) group and the (CB[7](−), ADA(+)) group showed modestly elevated fluorescence (1.3–1.5-fold that of the control group), consistent with the results observed under CLSM. As intracellular ROS play a key role in killing the internalized *E. coli*, the viability of the intracellular bacteria was evaluated by using the bacterial live/dead staining assays at 18 h after infection. Intense red signals were found inside the macrophages of all groups, suggesting that most of the intracellular *E. coli* were dead. Of a significant note, more red fluorescence, indicative of dead bacteria, was observed in the SAR-Macrophage (Fig. S12, ESI[†]). These results indicated that the SAR-Macrophages exhibited an enhanced recognition and




Fig. 2 (A) SEM images of macrophages and *E. coli* with different formulations (CB[7](−), ADA(−)); (CB[7](+), ADA(−)); (CB[7](−), ADA(+)) and (CB[7](+), ADA(+)) (infected with MOI = 10, 100 min). (B) Intracellular ROS generation of different formulations of the macrophage after infecting *E. coli* including (CB[7](−), ADA(−)); (CB[7](−), ADA(+)); (CB[7](+), ADA(−)) and (CB[7](+), ADA(+)), respectively, followed by the evaluation of the intracellular ROS by DCFHDA staining and imaging under CLSM.

arrest of extracellular bacteria and effectively killed bacteria *via* M1 polarization.

Plate counting assay was subsequently adopted to confirm the antibacterial activities of the SAR-Macrophage. It was shown that after treatment with (CB[7](+), ADA(+)), plate counting results confirmed the remarkable antibacterial activity of the SAR-Macrophage towards *E. coli*, which was comparable to, but not as good as, the first-line antibiotics, such as ampicillin and ofloxacin, which was not unexpected because here *E. coli* is a regular strain sensitive to antibiotics (Fig. S13, ESI†). To assess the effective therapeutic dose range, different quantities of SAR-Macrophages were added to *E. coli*, as shown in Fig. S14 (ESI†), and the SAR-Macrophage (CB[7](+), ADA(+)) exhibited decent antibacterial effects even at a concentration of 10^3 mL^{-1} . In contrast, in the presence of the same quantity of regular macrophages, there were much more bacteria that survived, confirming that the strong and specific host-guest interaction was the main reason for the enhanced antibacterial properties.

Furthermore, in order to show the unique advantages of the SAR-Macrophage against drug-resistant bacteria, Uropathogenic *Escherichia coli* Y9 (UPEC), which is a type of clinically isolated drug-resistant bacterium,³⁰ was employed in our antibacterial studies and compared against a couple of classic antibiotics. As shown in Fig. S15 (ESI†), the first-line

antibiotics, such as ampicillin and ofloxacin, exhibited little antibacterial activities against UPEC due to the well-developed antibiotic resistance of UPEC. In contrast, after treatment with the SAR-Macrophage (CB[7](+), ADA(+)), the survival of UPEC decreased significantly, indicating the effective antibacterial capability of the SAR-Macrophage to the drug-resistant strains, which was otherwise not achievable by regular macrophages.

The recognition and arrest of *E. coli* by the SAR-Macrophages were further investigated in zebrafish *in vivo*, as immune-capture of bacteria usually takes place in the circulatory system, and this transparent animal modal allows a direct visualization of the arrest process in the fish body at a single cell level.³¹ After sequentially injecting DiD-labeled RAW 264.7 cells into the common cardinal vein (CCV) of zebrafish larvae (48 hpf (hours post fertilization)) and GFP-expressed *E. coli* into the dorsal vein for free circulation, the red-fluorescence macrophages could not catch the green-fluorescence *E. coli* efficiently in the fast-circulating blood system (Fig. 3). In dramatic contrast, the SAR-Macrophages caught ADA-decorated *E. coli* in a rather efficient manner, as was evidenced by the overlapped DiD and GFP fluorescence *in vivo*. These data showed that the DiD-labeled SAR-Macrophages efficiently recognized and captured pathogens in living zebrafish.

To further evaluate the applicability of the SAR-Macrophage in the fight against pathogen infection *in vivo*, a mouse wound




Fig. 3 (A) Scheme showing a two-step injection of the macrophage and *E. coli* into zebrafish. (B) Representative CLSM images and corresponding quantification of GFP- (green) and DiD- (red) co-localization in zebrafish, showing the binding between DiD-loaded RAW 264.7 and GFP-expressed *E. coli*, with different formulations, including (CB[7](-), ADA(-)), (CB[7](+), ADA(-)), (CB[7](-), ADA(+)) and (CB[7](+), ADA(+)), respectively. For the macrophage, approximately 100–200 cells with DiD fluorescent labeling were injected into the common cardinal vein (CCV) of the fish larvae (48 hpf). For bacteria, approximately 1000–2000 CFU were injected into the vein to allow circulation.




Fig. 4 (A) Scheme showing *E. coli* infection (10^7 CFU, 1×10^9 CFU per mL for 10 μ L of *E. coli*) in a skin wound on mouse and the two-step injection therapeutic process (first injection of mannose-ADA ($50 \mu\text{g mL}^{-1}$) and second injection of the SAR-Macrophage (10^5 , 10^6 mL^{-1} for 100 μ L)) ($n = 3$ in each group). (B) Photographs of the wounds of mice infected with *E. coli* after treatment with PBS, (CB[7](-), ADA(-)), (CB[7](+), ADA(-)), (CB[7](-), ADA(+)) and (CB[7](+), ADA(+)), respectively on Day 1, 3, 5, 7, 9 and 11. (C) The evolving wound area in mice skin during the treatment in each group. (D) Quantitative analysis of the bacterial colony in the wound tissue after treatment for 5 days in each group. (E) The H&E staining of wound tissue sections after treatment with PBS, (CB[7](-), ADA(-)), (CB[7](+), ADA(-)), (CB[7](-), ADA(+)) and (CB[7](+), ADA(+)), respectively (red arrows indicate inflammatory cells; blue arrows indicate collagenous fiber; green arrows indicate new blood vessels).

infection model was established, where full-thickness wounds were created with a 6 mm biopsy punch on the back of mice and were subsequently infected with *E. coli* ($10 \mu\text{L}$, 1×10^9 CFU per mL). After the mice underwent infection for 4 h, the wound area was treated with mannose-ADA and the SAR-Macrophage (10^5 cells) sequentially, with a 1 h gap between the two injections for the (CB[7](+), ADA(+)) group (Fig. 4A). As shown in Fig. 4B and C, the (CB[7](+), ADA(+)) group of mice exhibited a rapid wound healing process, with the scabbed

wound of only 22% that of the original area on Day 5, attributed to the fast recognition and elimination of mannose-ADA labeled *E. coli* by the SAR-Macrophage. In contrast, in the other treatment groups, the wounds changed from a clear raw appearance to yellowish dense mucus, and recovered slowly. The wound tissues from the infected areas were removed on Day 5 for the quantitative analysis of viable bacteria. As shown in Fig. 4D and Fig. S16 (ESI[†]), (CB[7](+), ADA(+)) exhibited superior antibacterial effects and significantly lowered the

number of bacteria in the infectious tissue, when compared with other groups. In addition, dramatically reduced inflammatory infiltration and more newly formed collagen and blood vessels were observed in the (CB[7](+), ADA(+)) treated group, when compared with other groups (Fig. 4E). Major organs of the mice showed no obvious damage, indicating the decent biosafety of this therapeutic approach (Fig. S17, ESI†). Collectively, these results demonstrated that the sequential injection of mannose-ADA and the SAR-Macrophage afforded excellent antibacterial effects in a mammal model, suggesting a significant potential for clinical translation.

Conclusions

A SAR-Macrophage was developed and applied for the first time to enhance the recognition and latching of bacteria, mediated *via* strong and multipoint host-guest interactions between the artificial receptors (CB[7]) on the macrophage and the guest ligands (ADA) on *E. coli*. The SAR-Macrophage was shown to rapidly recognize, efficiently internalize and exterminate guest-anchored *E. coli* both *in vitro* and *in vivo*, resulting in M1 polarization and ROS generation for the effective intracellular bacteria inhibition. More importantly, the SAR-Macrophage showed powerful antibacterial effects in drug-resistant *E. coli* strain, UPEC, where common antibiotics exhibited little antibacterial activities. In this approach, mannose-ADA was designed and employed to specifically pre-target and anchor ADA on the surface of *E. coli*, facilitating the targeted recognition and arresting by the SAR-Macrophage. Although mannose-ADA could not be extended to other bacterial strains than *E. coli*, the SAR-Macrophage could be applied to a variety of other pathogens, in principle, as long as pathogens could be remotely modified with ADA *via* other ligand-receptor interactions, similar to mannose-FimH interactions. Nevertheless, the SAR-Macrophage, reminiscent of CAR-Macrophage, not only represents a simple cell-engineering approach for potential antibacterial applications, but also provides important new insights to design and develop cell-based therapeutics for diverse biomedical applications *via* an enhanced target-recognition.

Author contributions

This project was conceptually designed by QC and RW. The majority of the experiments were conducted by QC, assisted by MX, CS, KY, ZY and JL. Data analysis was conducted by QC, JZ, YZ and RW. The manuscript was prepared by QC and RW. All authors discussed the results and commented on the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The Science and Technology Development Fund (FDCT), Macau SAR (file no.: 0065/2021/A2), the National Natural Science

Foundation of China (21871301 and 22071275), and Dr. Stanley Ho Medical Development Foundation (SHMDF-OIRFS/2021/002) are gratefully acknowledged for providing financial support to this work.

Notes and references

- 1 R. Partridge Sally, M. Kwong Stephen, N. Firth and O. Jensen Slade, *Clin. Microbiol. Rev.*, 2018, **31**, e00088–e00017.
- 2 M. Tyers and G. D. Wright, *Nat. Rev. Microbiol.*, 2019, **17**, 141–155.
- 3 A. J. Wolf and D. M. Underhill, *Nat. Rev. Immunol.*, 2018, **18**, 243–254.
- 4 P. J. Murray, *Annu. Rev. Physiol.*, 2017, **79**, 541–566.
- 5 G. Weiss and U. E. Schaible, *Immunol. Rev.*, 2015, **264**, 182–203.
- 6 K. B. R. Belchamber, R. Singh, C. M. Batista, M. K. Whyte, D. H. Dockrell, I. Kilty, M. J. Robinson, J. A. Wedzicha, P. J. Barnes and L. E. Donnelly, *Eur. Respir. J.*, 2019, **54**, 1802244.
- 7 S. Das, K. A. Owen, K. T. Ly, D. Park, S. G. Black, J. M. Wilson, C. D. Sifri, K. S. Ravichandran, P. B. Ernst and J. E. Casanova, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 2136–2141.
- 8 C. Fontaine, E. Rigamonti, A. Nohara, P. Gervois, E. Teissier, J.-C. Fruchart, B. Staels and G. Chinetti-Gbaguidi, *Circ. Res.*, 2007, **101**, 40–49.
- 9 C. J. Harvey, R. K. Thimmulappa, S. Sethi, X. Kong, L. Yarmus, R. H. Brown, D. Feller-Kopman, R. Wise and S. Biswal, *Sci. Transl. Med.*, 2011, **3**, 78ra32.
- 10 S. Watanabe, M. Alexander, A. V. Misharin and G. R. S. Budinger, *J. Clin. Invest.*, 2019, **129**, 2619–2628.
- 11 D. G. DeNardo and B. Ruffell, *Nat. Rev. Immunol.*, 2019, **19**, 369–382.
- 12 Y. Sun, Y. Liu, B. Zhang, S. Shi, T. Zhang, D. Zhao, T. Tian, Q. Li and Y. Lin, *Bioact. Mater.*, 2021, **6**, 2281–2290.
- 13 Y. Yang, X. Wu, L. Ma, C. He, S. Cao, Y. Long, J. Huang, R. D. Rodriguez, C. Cheng, C. Zhao and L. Qiu, *Adv. Mater.*, 2021, **33**, 2005477.
- 14 X. Fan, X. Wu, F. Yang, L. Wang, K. Ludwig, L. Ma, A. Trampuz, C. Cheng and R. Haag, *Angew. Chem., Int. Ed.*, 2021, DOI: 10.1002/anie.202113833.
- 15 L. Li, L. Cao, X. Xiang, X. Wu, L. Ma, F. Chen, S. Cao, C. Cheng, D. Deng and L. Qiu, *Adv. Funct. Mater.*, 2021, **31**, 2107530.
- 16 X. Fan, F. Yang, C. Nie, L. Ma, C. Cheng and R. Haag, *Adv. Mater.*, 2021, **33**, 2100637.
- 17 M. J. Webber and R. Langer, *Chem. Soc. Rev.*, 2017, **46**, 6600–6620.
- 18 J. Zhou, G. Yu and F. Huang, *Chem. Soc. Rev.*, 2017, **46**, 7021–7053.
- 19 W. Li, K. Dong, H. Wang, P. Zhang, Y. Sang, J. Ren and X. Qu, *Biomaterials*, 2019, **217**, 119310.
- 20 X. Ma and Y. Zhao, *Chem. Rev.*, 2015, **115**, 7794–7839.
- 21 X. Li, H. Bai, Y. Yang, J. Yoon, S. Wang and X. Zhang, *Adv. Mater.*, 2019, **31**, 1805092.

- 22 K. L. Kim, G. Sung, J. Sim, J. Murray, M. Li, A. Lee, A. Shrinidhi, K. M. Park and K. Kim, *Nat. Commun.*, 2018, **9**, 1712.
- 23 C. Sun, Z. Wang, L. Yue, Q. Huang, Q. Cheng and R. Wang, *J. Am. Chem. Soc.*, 2020, **142**, 16523–16527.
- 24 W. Liu, S. K. Samanta, B. D. Smith and L. Isaacs, *Chem. Soc. Rev.*, 2017, **46**, 2391–2403.
- 25 K. Newick, S. O'Brien, E. Moon and S. M. Albelda, *Annu. Rev. Med.*, 2017, **68**, 139–152.
- 26 M. Klichinsky, M. Ruella, O. Shestova, X. M. Lu, A. Best, M. Zeeman, M. Schmierer, K. Gabrusiewicz, N. R. Anderson, N. E. Petty, K. D. Cummins, F. Shen, X. Shan, K. Veliz, K. Blouch, Y. Yashiro-Ohtani, S. S. Kenderian, M. Y. Kim, R. S. O'Connor, S. R. Wallace, M. S. Kozłowski, D. M. Marchione, M. Shestov, B. A. Garcia, C. H. June and S. Gill, *Nat. Biotechnol.*, 2020, **38**, 947–953.
- 27 C. Gao, Q. Cheng, J. Li, J. Chen, Q. Wang, J. Wei, Q. Huang, S. M. Y. Lee, D. Gu and R. Wang, *Adv. Funct. Mater.*, 2021, **31**, 2102440.
- 28 C. Gao, Q. Cheng, J. Wei, C. Sun, S. Lu, C. H. T. Kwong, S. M. Y. Lee, Z. Zhong and R. Wang, *Mater. Today*, 2020, **40**, 9–17.
- 29 Z. Wang, Y. Zhang, E. Ju, Z. Liu, F. Cao, Z. Chen, J. Ren and X. Qu, *Nat. Commun.*, 2018, **9**, 3334.
- 30 Z.-x. Cheng, C. Guo, Z.-g. Chen, T.-c. Yang, J.-y. Zhang, J. Wang, J.-x. Zhu, D. Li, T.-t. Zhang, H. Li, B. Peng and X.-x. Peng, *Nat. Commun.*, 2019, **10**, 3325.
- 31 X. He, X. Yin, J. Wu, S. L. Wickström, Y. Duo, Q. Du, S. Qin, S. Yao, X. Jing, K. Hosaka, J. Wu, L. D. Jensen, A. Lundqvist, A. I. Salter, L. Bräutigam, W. Tao, Y. Chen, R. Kiessling and Y. Cao, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 22910–22919.